The SEC has issued a cease and desist order to FibroGen Inc, a biotech company headquartered in San Francisco, finding that it, mainly through its chief medical officer, made false and/or materially misleading disclosures in a range of forums, including a high-profile industry presentation, multiple SEC filings, an earnings call,
Free Trial
Register for free to keep reading.
To continue reading this article and unlock full access to GRIP, register now. You’ll enjoy free access to all content until our subscription service launches in early 2026.
- Unlimited access to industry insights
- Stay on top of key rules and regulatory changes with our Rules Navigator
- Ad-free experience with no distractions
- Regular podcasts from trusted external experts
- Fresh compliance and regulatory content every day
